KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice
- 23 February 2017
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 140 (8) , 1860-1869
Abstract
Ovarian carcinosarcoma cancer is the most lethal form of gynecological malignancy, but the pathogenesis and biological function for this ovarian cancer remain unknown. We establishment the transgenic mouse model of K-rasG12Dp53loxP/loxP and found that K-ras mutation and p53 deletion within the ovarian surface epithelium gave rise to ovarian lesions with a hyperproliferation and endometrioid glandular morphology. Furthermore, double mutant ovaries formed ovarian carcinosarcomas that were high grade and poorly differentiated. Induction was widely metastatic and spread to abdominal organs including liver, spleen, and kidney at 4 wk. We also confirmed the role of K-rasG12D in ovarian cancer cell lines MCAS and PA-1 and showed that K-rasG12D overexpression strongly induced cell proliferation, migration, and invasion. The ovarian cancer model we developed recapitulates the specific tumor histomorphology and the probable mechanism of malignant transformation in endometriosis.Keywords
This publication has 38 references indexed in Scilit:
- KRAS and MAPK1 Gene Amplification in Type II Ovarian CarcinomasInternational Journal of Molecular Sciences, 2013
- Therapeutic strategies in epithelial ovarian cancerJournal of Experimental & Clinical Cancer Research, 2012
- High-grade serous ovarian cancer arises from fallopian tube in a mouse modelProceedings of the National Academy of Sciences, 2012
- An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceJournal of Clinical Investigation, 2012
- Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid AdenocarcinomaClinical Cancer Research, 2011
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53PLOS ONE, 2009
- Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated LiposarcomasClinical Cancer Research, 2009
- Role of p53 and Rb in Ovarian Cancer2008
- A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation.Journal of Cell Biology, 1986